Parliamentary Search

Written question asked by Kerry McCarthy (Labour) on Wednesday, 15 April 2026, in the House of Commons. It was due for an answer on Wednesday, 22 April 2026 (named day). A holding answer was provided on Thursday, 23 April 2026. A substantive answer was provided by Zubir Ahmed (Labour) on Wednesday, 29 April 2026 on behalf of the Department of Health and Social Care.

Advanced Therapy Medicinal Products

Question

To ask the Secretary of State for Health and Social Care, whether he has had discussions with colleagues in NHS England on the development of a regenerative medicine strategy.

Answer

No such discussions have taken place. The Government is committed to ensuring the United Kingdom remains a global leader in the development of advanced therapies, including regenerative medicines, to drive innovation in the National Health Service and deliver life-changing outcomes for patients. The Department continues to work with public sector partners to promote a joined-up ecosystem that will support the development, regulation, and delivery of advanced therapies.

The Government invests in research into regenerative medicine and advanced therapies through UK Research and Innovation. The £42 million UK Regenerative Medicine Platform (UKRMP) aimed at addressing the key translational challenges in regenerative medicine and at bringing innovative regenerative medicine therapies to the clinic. In its second phase, from 2018 to 2024, the UKRMP established three hubs: the Engineered Cell Environment Hub; the Smart Materials Hub; and the Pluripotent Stem Cells and Engineered Cells Hub.

Secondary information

Type
Written question
Reference
127428
Session
2024-26
Subjects
Advanced therapy medicinal products
Link
View this Written question on www.parliament.uk